Search for Clinical Trial Results
Peripheral T-cell Lymphoma - 26 Studies Found
Status | Study |
Completed |
Study Name: Study of Pralatrexate With Vitamin B12 and Folic Acid in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Condition: Peripheral T-cell Lymphoma Date: 2006-08-14 Interventions: Drug: Pralatrexate Injection Pralatrexate 30 mg/m2 via IV push over 3-5 minutes for 6 weeks in a 7 week |
Recruiting |
Study Name: Chidamide for Refractory/Relapsed Peripheral T Cell Lymphoma Condition: Peripheral T Cell Lymphoma Date: 2016-10-21 Interventions: Drug: Chidamide Chidamide is given to the patients as described, and drug concentration is measured in p |
Completed |
Study Name: E7777 for the Treatment of Patients With Peripheral T-Cell Lymphoma Condition: Peripheral T-Cell Lymphoma Date: 2011-07-18 Interventions: Biological: denileukin diftitox (E7777) E7777 will be administered by intravenous (IV) infusion for 5 da |
Active, not recruiting |
Study Name: Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry Condition: Peripheral T-cell Lymphoma Date: 2010-04-23 |
Not yet recruiting |
Study Name: Chidamide With ICE Regimen for Relapsed/Refractory Peripheral T Cell Lymphoma Condition: Peripheral T Cell Lymphoma Date: 2016-07-24 Interventions: Drug: Chidamide with ICE regimen Chidamide and ICE regimen, dosage described in arm description |
Recruiting |
Study Name: Chidamide Plus Chemotherapy in the Treatment of Peripheral T-cell Lymphoma Condition: Peripheral T Cell Lymphoma Date: 2016-04-19 Interventions: Drug: Chidamide |
Completed |
Study Name: Alemtuzumab and CHOP Chemotherapy for Aggressive Histological Peripheral T-Cell Lymphomas Condition: Peripheral T-cell Lymphomas Date: 2007-03-27 Interventions: Drug: Alemtuzumab (Campath-1H) The investigational drug is alemtuzumab (Campath-1H). It is a recombinant |
Completed |
Study Name: A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL) Condition: Peripheral T-cell Lymphoma Date: 2011-09-13 Interventions:
|
Active, not recruiting |
Study Name: Phase I/II Clinical Study of Pralatrexate in Japanese Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Condition: Peripheral T-cell Lymphoma Date: 2013-12-04 Interventions:
|
Recruiting |
Study Name: A Phase 2 Study of SP-02L in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) Condition: Peripheral T-Cell Lymphoma Date: 2015-12-25 Interventions: Drug: SP-02L (darinaparsin for injection) Darinaparsin 300 mg/m2 once daily for 5 consecutive days every |